An Empirical Investigation of the U.S. Corporate Leniency Program *

Abstract This project measures the impact on U.S. public companies of the amendment to th

Brinell Limit Testing Machine - Final Design Report

In keeping with the California Polytechnic State University motto of “Learn by Doing”, this project was performed by Mechanical Engineering students Joe Cloutier, Josh Kessler, and Mike Jaskulsky II as their senior project. Starting in the Fall 2009 quarter and reaching completion with the end of the Spring 2010 quarter, this project provided these students with experience in application of a formal engineering design process in the solving of an open-ended engineering design problem, in developing and maintaining an engineering project schedule, as well as providing further experience working on an engineering team. As the engineers of Parker Aerospace seek to use different metals in their high performance bearing applications than have traditionally been used in the past, often the data does not exist for them to be able to accurately design against brinelling. To provide their engineers with this data, Parker Aerospace proposed the following as a senior project to Cal Poly’s seniors. They requested that a team of engineering students would design, fabricate, assemble, and validate through testing a machine that would determine the loads at the onset of brinelling for different metals and would allow for multiple measurements to be taken from each set of sample materials tested. Some of the secondary design requirements were for the test fixture to be portable, small enough to be used as a desktop unit, be able to accommodate a thermal chamber around the test area, and also provide measurements of the total deformation of the sample materials when under load. Also, time allowing, Parker Aerospace requested that the senior project team devote the last part of the last quarter to using the machine to provide data for a number of materials that they will provide. The loads that the test machine would need to deliver to test all material samples to the onset of brinelling were determined through hertzian contact stress analysis. These calculated loads were then used to determine the deflection of the sample materials, allowing for the sizing of structural components and selection of necessary sensors. The design for the fixture was developed around the initial design concept displayed in the Project Proposal by Parker Aerospace. After developing a number of different designs and variations of specific components of the fixture, the best of these design variations were presented to a panel of Parker Aerospace’s engineers during a Preliminary Design Review. From these designs, a final design was selected and various modifications were made as suggested by Parker. A final design was decided on and the rest of the project was completed by the end of the Spring quarter

Spacecraft design project: High latitude communications satellite

The spacecraft design project was part of AE-4871, Advanced Spacecraft Design. The project was intended to provide experience in the design of all major components of a satellite. Each member of the class was given primary responsibility for a subsystem or design support function. Support was requested from the Naval Research Laboratory to augment the Naval Postgraduate School faculty. Analysis and design of each subsystem was done to the extent possible within the constraints of an eleven week quarter and the design facilities (hardware and software) available. The project team chose to evaluate the design of a high latitude communications satellite as representative of the design issues and tradeoffs necessary for a wide range of satellites. The High-Latitude Communications Satellite (HILACS) will provide a continuous UHF communications link between stations located north of the region covered by geosynchronous communications satellites, i.e., the area above approximately 60 N latitude. HILACS will also provide a communications link to stations below 60 N via a relay Net Control Station (NCS), which is located with access to both the HILACS and geosynchronous communications satellites. The communications payload will operate only for that portion of the orbit necessary to provide specified coverage

X-38 Advanced Sublimator

A document discusses a heat rejection device for transferring heat from a space vehicle by venting water into space through the use of a novel, two-stage water distribution system. The system consists of two different, porous media that stop water-borne contaminants from clogging the system and causing operational failures. Feedwater passes through a small nozzle, then into a porous disk made of sintered stainless steel, and then finally into large-pore aluminum foam. The smaller pore layer of the steel disk controls the pressure drop of the feedwater. The ice forms in the foam layer, and then sublimates, leaving any contaminants behind. The pore-size of the foam is two orders of magnitude larger than the current porous plate sublimators, allowing for a greater tolerance for contaminants. Using metallic fibers in the foam also negates problems with compression seen in the use of poly(tetrafluoroethylene) felt

Identification of a Putative Crf Splice Variant and Generation of Recombinant Antibodies for the Specific Detection of Aspergillus fumigatus

BACKGROUND: Aspergillus fumigatus is a common airborne fungal pathogen for humans. It frequently causes an invasive aspergillosis (IA) in immunocompromised patients with poor prognosis. Potent antifungal drugs are very expensive and cause serious adverse effects. Their correct application requires an early and specific diagnosis of IA, which is still not properly achievable. This work aims to a specific detection of A. fumigatus by immunofluorescence and the generation of recombinant antibodies for the detection of A. fumigatus by ELISA. RESULTS: The A. fumigatus antigen Crf2 was isolated from a human patient with proven IA. It is a novel variant of a group of surface proteins (Crf1, Asp f9, Asp f16) which belong to the glycosylhydrolase family. Single chain fragment variables (scFvs) were obtained by phage display from a human naive antibody gene library and an immune antibody gene library generated from a macaque immunized with recombinant Crf2. Two different selection strategies were performed and shown to influence the selection of scFvs recognizing the Crf2 antigen in its native conformation. Using these antibodies, Crf2 was localized in growing hyphae of A. fumigatus but not in spores. In addition, the antibodies allowed differentiation between A. fumigatus and related Aspergillus species or Candida albicans by immunofluorescence microscopy. The scFv antibody clones were further characterized for their affinity, the nature of their epitope, their serum stability and their detection limit of Crf2 in human serum. CONCLUSION: Crf2 and the corresponding recombinant antibodies offer a novel approach for the early diagnostics of IA caused by A. fumigatus

Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.

Importance: Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited. Objective: To determine whether hydrocortisone improves outcome for patients with severe COVID-19. Design, Setting, and Participants: An ongoing adaptive platform trial testing multiple interventions within multiple therapeutic domains, for example, antiviral agents, corticosteroids, or immunoglobulin. Between March 9 and June 17, 2020, 614 adult patients with suspected or confirmed COVID-19 were enrolled and randomized within at least 1 domain following admission to an intensive care unit (ICU) for respiratory or cardiovascular organ support at 121 sites in 8 countries. Of these, 403 were randomized to open-label interventions within the corticosteroid domain. The domain was halted after results from another trial were released. Follow-up ended August 12, 2020. Interventions: The corticosteroid domain randomized participants to a fixed 7-day course of intravenous hydrocortisone (50 mg or 100 mg every 6 hours) (n = 143), a shock-dependent course (50 mg every 6 hours when shock was clinically evident) (n = 152), or no hydrocortisone (n = 108). Main Outcomes and Measures: The primary end point was organ support-free days (days alive and free of ICU-based respiratory or cardiovascular support) within 21 days, where patients who died were assigned -1 day. The primary analysis was a bayesian cumulative logistic model that included all patients enrolled with severe COVID-19, adjusting for age, sex, site, region, time, assignment to interventions within other domains, and domain and intervention eligibility. Superiority was defined as the posterior probability of an odds ratio greater than 1 (threshold for trial conclusion of superiority >99%). Results: After excluding 19 participants who withdrew consent, there were 384 patients (mean age, 60 years; 29% female) randomized to the fixed-dose (n = 137), shock-dependent (n = 146), and no (n = 101) hydrocortisone groups; 379 (99%) completed the study and were included in the analysis. The mean age for the 3 groups ranged between 59.5 and 60.4 years; most patients were male (range, 70.6%-71.5%); mean body mass index ranged between 29.7 and 30.9; and patients receiving mechanical ventilation ranged between 50.0% and 63.5%. For the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively, the median organ support-free days were 0 (IQR, -1 to 15), 0 (IQR, -1 to 13), and 0 (-1 to 11) days (composed of 30%, 26%, and 33% mortality rates and 11.5, 9.5, and 6 median organ support-free days among survivors). The median adjusted odds ratio and bayesian probability of superiority were 1.43 (95% credible interval, 0.91-2.27) and 93% for fixed-dose hydrocortisone, respectively, and were 1.22 (95% credible interval, 0.76-1.94) and 80% for shock-dependent hydrocortisone compared with no hydrocortisone. Serious adverse events were reported in 4 (3%), 5 (3%), and 1 (1%) patients in the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively. Conclusions and Relevance: Among patients with severe COVID-19, treatment with a 7-day fixed-dose course of hydrocortisone or shock-dependent dosing of hydrocortisone, compared with no hydrocortisone, resulted in 93% and 80% probabilities of superiority with regard to the odds of improvement in organ support-free days within 21 days. However, the trial was stopped early and no treatment strategy met prespecified criteria for statistical superiority, precluding definitive conclusions. Trial Registration: ClinicalTrials.gov Identifier: NCT02735707

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

Q&A (LIVE): Searching for OER: Making Your Open Resources Discoverable

Q&A session for Searching for OER: Making Your Open Resources Discoverable. Moderator: Mike Monac

Positional cloning of ZNF217 and NABC1: Genes amplified at 20q13.2 and overexpressed in breast carcinoma

We report here the molecular cloning of an approximately 1-Mb region of recurrent amplification at 20q13.2 in breast cancer and other tumors and the delineation of a 260-kb common region of amplification. Analysis of the 1-Mb region produced evidence for five genes, ZNF217, ZNF218, and NABC1, PIC1L (PIC1-like), CYP24, and a pseudogene CRP (Cyclophillin Related Pseudogene). ZNF217 and NABC1 emerged as strong candidate oncogenes and were characterized in detail. NABC1 is predicted to encode a 585-aa protein of unknown function and is overexpressed in most but not all breast cancer cell lines in which it was amplified. ZNF217 is centrally located in the 260-kb common region of amplification, transcribed in multiple normal tissues, and overexpressed in all cell lines and tumors in which it is amplified and in two in which it is not. ZNF217 is predicted to encode alternately spliced, Kruppel-like transcription factors of 1,062 and 1,108 aa, each having a DNA-binding domain (eight C2H2 zinc fingers) and a proline-rich transcription activation domain